Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Long-acting bNAbs can sustain extended ART-free viral control in people treated during early-stage HIV and represent a promising step towards achieving ART-free HIV remission.
Authors
- Nicola Robinson (ORCID: https://orcid.org/0000-0001-5256-4527)
- Ishrat Jahan (ORCID: https://orcid.org/0000-0002-7115-8468)
- Marcílio Jorge Fumagalli (ORCID: https://orcid.org/0000-0002-0207-5423)
- Panagiota Zacharopoulou (ORCID: https://orcid.org/0000-0002-3645-662X)
- Whitlock Gary
- Henrik Nielsen (ORCID: https://orcid.org/0000-0002-6773-1874)
- Cíntia Bittar (ORCID: https://orcid.org/0000-0002-2048-4589)
- Jacquie Ujetz
- Graham P. Taylor (ORCID: https://orcid.org/0000-0002-3773-2390)
- Mohammed Altaf (ORCID: https://orcid.org/0000-0001-6977-781X)
- Jesper Damsgaard Gunst (ORCID: https://orcid.org/0000-0002-3787-0259)
- Jesal Gohil (ORCID: https://orcid.org/0000-0001-5708-6317)
- Timothy Tipoe (ORCID: https://orcid.org/0000-0001-5767-9665)
- Margaret E. Ackerman (ORCID: https://orcid.org/0000-0002-4253-3476)
- Rebecca Sutherland (ORCID: https://orcid.org/0000-0001-5214-9630)
- Louise-Rae Cherrill
- Tamara Elliott (ORCID: https://orcid.org/0000-0001-8232-9413)
- Kyle Ring (ORCID: https://orcid.org/0000-0003-4016-4643)
- Lisa Hamzah
- Sarah Pett (ORCID: https://orcid.org/0000-0002-1882-509X)
- Sabine Kinloch
- J. Weiner (ORCID: https://orcid.org/0000-0002-9762-7840)
- Frater John
- Jill Horowitz
- Irvine Mangawa
- Piyumika Godakandaarachi
- Emanuela Falaschetti
- Paola Cicconi
- Alison J. Uriel
- Simon Collins
- Stephen Fletcher
- Kelly Seaton
- Ole Sogaard
- Ming Lee
- RIO Trial Investigators
- Hanna Box
- Sarah Fidler
- Julie Fox
- Anna Kaczysnka
- Marta Boffito
- Chloe Orkin
- Helen Brown
- Amanda Clarke
- Georgia Tomaras
Institutions
- Dartmouth College (US)
- NHS Lothian (GB)
- Howard Hughes Medical Institute (US)
- Imperial College Healthcare NHS Trust (GB)
- Queen Mary University of London (GB)
- Royal Free London NHS Foundation Trust (GB)
- Duke University (US)
- Chinese University of Hong Kong (HK)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Central and North West London NHS Foundation Trust (GB)
- Barts Health NHS Trust (GB)
- Aalborg University Hospital (DK)
- Western General Hospital (GB)
- St George’s University Hospitals NHS Foundation Trust (GB)
- Nuffield Orthopaedic Centre (GB)
- Aarhus University Hospital (DK)
- National Institute for Health and Care Research (GB)
- Manchester University NHS Foundation Trust (GB)
- Thomas Foundation (AU)
- NIHR Imperial Biomedical Research Centre (GB)
- British HIV Association (GB)
- Chelsea and Westminster Hospital (GB)
- Norwegian Womens Public Health Association (NO)
- Oxford University Hospitals NHS Trust (GB)
- University Hospitals Sussex NHS Foundation Trust (GB)
- University College London (GB)
- Imperial College London (GB)
- Rockefeller University (US)
- Aalborg University (DK)
Publication Details
- Journal
- medRxiv
- Published
- 2026-02-04
- DOI
- https://doi.org/10.64898/2026.02.04.25342277
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Howard Hughes Medical Institute
- Bill and Melinda Gates Foundation
- Israel Cancer Research Fund
- National Institute for Health and Care Research
- National Institutes of Health
- Center for AIDS Research, University of Washington
- Medical Research Council
- NIHR Imperial Biomedical Research Centre
- NIHR Oxford Biomedical Research Centre